TL;DR
- Release Date & Time: Tuesday, October 13, 2026, Before Market Open (Q3 2026)
- Consensus Estimates: EPS of $4.12 | Revenue of $111.38 Billion
- Options-Implied Move: ±6.86% (~$26.00 move based on $379.30 close)
- Single Biggest Swing Factor: Medical Care Ratio (MCR) containment against industry-wide medical cost inflation, alongside management's strategy to offset Medicare Advantage Star Rating cuts.
Setup Overview
UnitedHealth Group (UNH) enters its Q3 2026 earnings print in a complex structural setup. While sell-side estimate revisions have trended upward heading into the report, market sentiment is tempered by broader sector cross-currents. Peers Elevance Health (ELV) and Humana (HUM) recently reported elevated benefit expense ratios (89.7% and 91.2%, respectively), highlighting persistent medical utilization pressures across managed care.
Management previously raised FY2026 adjusted EPS guidance to $19.50–$20.00 (from >$18.25) during Q2 results, while narrowing full-year MCR guidance to 88.1% ± 25 bps. However, early October CMS data revealed a sharp drop in UNH’s 2027 Medicare Advantage Star Ratings, with members in 4+ star plans falling to ~66.8% (down from ~81%). Although UNH is actively mitigating unprofitable exposure—discontinuing plans covering ~390,000 members for 2027—investors remain focused on whether Optum's growth can insulate earnings from core insurance margin compression.
Historical Pattern
UNH holds an EPS beat rate of 75% over the past 8 quarters (6 beats, 2 misses). However, price action shows an asymmetric reaction: the market frequently sells off post-earnings even following EPS beats.
| Period | EPS Result | Post-Earnings Stock Reaction |
|---|---|---|
| Q2 2026 | Beat | +1.16% |
| Q1 2026 | Beat | +6.96% |
| Q4 2025 | Beat | -19.61% |
| Q3 2025 | Beat | +0.51% |
| Q2 2025 | Miss | -7.50% |
| Q1 2025 | Miss | -21.50% |
| Q4 2024 | Beat | -2.70% |
| Q3 2024 | Beat | -4.70% |
Key Takeaway: Five of the last eight quarterly prints resulted in immediate negative price reactions despite six EPS beats. The stock exhibits elevated vulnerability to medical cost surprises or long-term guidance revisions, where minor execution missteps have historically triggered double-digit drawdowns.
What to Watch
- Q3 Medical Care Ratio (MCR): Tracked against the full-year target of 88.1% ± 25 bps. Any prints approaching or exceeding 89.0% will confirm sector-wide cost inflation fears.
- 2027 Star Ratings Mitigations: Clarity on how management plans to bridge potential revenue quality bonus headwinds from the Star Rating drop (~66.8% vs. peers like HUM at 93.4%).
- Optum Contribution: Performance across Optum Health and OptumInsight to gauge high-margin service growth off-setting health plan costs.
- FY26 Guidance Trajectory: Assess whether management maintains or narrows the $19.50–$20.00 EPS guidance window.